| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.19 | 0.2 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |